Harry Jenq's questions to ZFGN leadership • Q4 2015
Question
Harry Jenq, on behalf of JMP Securities, asked about hypothetical risk mitigation strategies for beloranib if it is confirmed to increase thrombotic events, such as patient subsetting or prophylactic medication, and how an overall benefit could be demonstrated.
Answer
CEO Tom Hughes outlined three primary strategies being considered: 1) enrolling low-risk patients with rigorous monitoring, 2) treating patients for thrombosis if abnormal values appear, or 3) administering prophylactic medication before starting treatment. He stated they would likely begin with a conservative approach to suppress risk and will provide updates after gaining clarity from the FDA.